Mirati Therapeutics

#3650

Rank

$2.34B

Marketcap

United States

Country

Leadership team

Mr. David D. Meek (CEO & Director)

Dr. Charles M. Baum M.D., Ph.D. (Founder, Pres, Head of R&D and Director)

Dr. James G. Christensen Ph.D. (Exec. VP & Chief Scientific Officer)

Products/ Services

Biopharma, Biotechnology, Medical

Number of Employees

100 - 500

Headquarters

San Diego, California, United States

Established

1995

Company Registration

SEC CIK number: 0001576263

Revenue

5M - 20M

Traded as

MRTX

Social Media

URL

https://www.mirati.com

Overview

Location

Recognition and Award

References

Summary

Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

History

Mirati Therapeutics works largely in KRAS-mutation inhibition, and developing treatments for tumors that contain it. The inhibition to the mutation has shown to shrink the size of its tumors. The company is based in San Diego, California. The company’s name comes from the Italian word for “targeted” . Mirati Therapeutics is traded on the NASDAQ under the ticker symbol MRTX. It joined the exchange in 2013.

Mission

Our mission is to develop innovative and targeted cancer therapies that improve patient outcomes.

Vision

Our vision is to make a lasting difference through the development of transformative therapies for the treatment of cancer.

Key Team

Mr. Benjamin J. Hickey M.B.A. (Chief Commercial Officer)

Ms. Laurie D. Stelzer (Chief Financial Officer)

Ms. Reena R. Desai (Chief Legal Officer & Corp. Sec.)

Mr. Michael E. Paolucci (Chief People Officer)

Dr. Kelly Covello Ph.D. (VP & Head of Medical Affairs)

Mr. Ryan Asay (VP & Head of Corp. Affairs)

Dr. Alan Bart Sandler M.D. (Exec. VP & Chief Medical Officer)

Recognition and Awards

Mirati has been recognized with numerous awards including the Investigational Drug of the Year Award, the Large Pharma Innovation Award, and the Best Drug Development Award. Mirati has also been included on the prestigious Fortune 500 list.